Glandular cell neoplasm
MONDO:0024276Also known as: glandular cell epithelial neoplasm, glandular cell epithelium neoplasm, glandular cell neoplasm, glandular cell tumor, glandular cell tumour
6470 clinical trials for this condition and its sub-types, 6 tagged with Glandular cell neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Glandular cell neoplasm
-
Adenocarcinoma 184 trials · 5,243 incl. sub-types
64 sub-types
- Hepatocellular carcinoma 1,043 trials · 1,088 incl. sub-types Sub-types →
- Pancreatic adenocarcinoma 493 trials · 926 incl. sub-types Sub-types →
- Renal cell carcinoma 611 trials · 710 incl. sub-types Sub-types →
- Tubular adenocarcinoma 0 trials · 557 incl. sub-types Sub-types →
- Colorectal adenocarcinoma 246 trials · 546 incl. sub-types Sub-types →
- Gastroesophageal junction adenocarcinoma 506 trials
- Gastric adenocarcinoma 448 trials · 480 incl. sub-types Sub-types →
- Bile duct adenocarcinoma 17 trials · 416 incl. sub-types Sub-types →
- Prostate adenocarcinoma 297 trials Sub-types →
- Breast adenocarcinoma 36 trials · 278 incl. sub-types Sub-types →
- Serous adenocarcinoma 6 trials · 241 incl. sub-types Sub-types →
- Ovarian adenocarcinoma 12 trials · 230 incl. sub-types Sub-types →
- Clear cell adenocarcinoma 14 trials · 201 incl. sub-types Sub-types →
- Esophageal adenocarcinoma 168 trials · 172 incl. sub-types Sub-types →
- Adenocarcinoma in situ 10 trials · 170 incl. sub-types Sub-types →
- Endometrioid adenocarcinoma 12 trials · 144 incl. sub-types Sub-types →
- Endometrium adenocarcinoma 30 trials · 118 incl. sub-types Sub-types →
- Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types Sub-types →
- Lung adenocarcinoma 114 trials · 117 incl. sub-types Sub-types →
- Gastroesophageal adenocarcinoma 93 trials
- Papillary adenocarcinoma 2 trials · 92 incl. sub-types Sub-types →
- Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types Sub-types →
- Small intestine adenocarcinoma 18 trials · 60 incl. sub-types Sub-types →
- Mucinous adenocarcinoma 18 trials · 57 incl. sub-types Sub-types →
- Adenoid cystic carcinoma 46 trials · 47 incl. sub-types Sub-types →
- Cervical adenocarcinoma 27 trials · 34 incl. sub-types Sub-types →
- Poorly differentiated thyroid gland carcinoma 17 trials
- Acinar cell carcinoma 4 trials · 15 incl. sub-types Sub-types →
- Signet ring cell carcinoma 4 trials · 11 incl. sub-types Sub-types →
- Paget disease 2 trials · 9 incl. sub-types Sub-types →
- Gallbladder adenocarcinoma 9 trials Sub-types →
- Bladder adenocarcinoma 5 trials · 8 incl. sub-types Sub-types →
- Vaginal adenocarcinoma 7 trials Sub-types →
- Cystadenocarcinoma 0 trials · 6 incl. sub-types Sub-types →
- Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types Sub-types →
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Parathyroid gland carcinoma 4 trials
- Pituitary adenocarcinoma 3 trials Sub-types →
- Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types Sub-types →
- Hepatoid adenocarcinoma 2 trials Sub-types →
- Mesonephric adenocarcinoma 2 trials Sub-types →
- Sweat gland carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Follicular variant thyroid gland papillary carcinoma 1 trial
- Micropapillary serous carcinoma 1 trial
- Nasal cavity adenocarcinoma 1 trial
- Seminal vesicle adenocarcinoma 1 trial
- Trabecular adenocarcinoma 1 trial
- Ureter adenocarcinoma 1 trial
- Adenoacanthoma 0 trials
- Epididymal adenocarcinoma 0 trials
- Ethmoid sinus adenocarcinoma 0 trials
- Granular cell carcinoma 0 trials
- Intestinal type adenocarcinoma 0 trials Sub-types →
- Lacrimal gland adenocarcinoma 0 trials Sub-types →
- Maxillary sinus adenocarcinoma 0 trials
- Middle ear adenocarcinoma 0 trials
- Minor salivary gland adenocarcinoma 0 trials Sub-types →
- Rete testis adenocarcinoma 0 trials
- Salivary gland basal cell adenocarcinoma 0 trials
- Scirrhous adenocarcinoma 0 trials
- Submandibular gland adenocarcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Villous adenocarcinoma 0 trials Sub-types →
-
Serous neoplasm 0 trials · 207 incl. sub-types
1 sub-type
- Ovarian serous tumor 6 trials · 207 incl. sub-types Sub-types →
-
Mucinous neoplasm 1 trial · 71 incl. sub-types
5 sub-types
- Mucin-producing carcinoma 0 trials · 58 incl. sub-types Sub-types →
- Pancreatic mucinous-cystic neoplasm 12 trials
- Fallopian tube mucinous tumor 1 trial · 10 incl. sub-types Sub-types →
- Mucinous cystadenoma 2 trials · 3 incl. sub-types Sub-types →
- Mucinous adenofibroma 0 trials Sub-types →
-
Cystadenoma 0 trials · 11 incl. sub-types
7 sub-types
- Serous cystadenoma 3 trials · 8 incl. sub-types Sub-types →
- Pancreatic cystadenoma 1 trial · 7 incl. sub-types Sub-types →
- Mucinous cystadenoma 2 trials · 3 incl. sub-types Sub-types →
- Bile duct cystadenoma 0 trials Sub-types →
- Ovarian cystadenoma 0 trials Sub-types →
- Papillary cystadenoma 0 trials Sub-types →
- Seminal vesicle cystadenoma 0 trials
-
Oncocytic neoplasm 0 trials · 7 incl. sub-types
2 sub-types
- Oncocytic adenoma 0 trials · 4 incl. sub-types Sub-types →
- Kidney oncocytoma 3 trials Sub-types →
-
Vaginal glandular neoplasm 0 trials · 7 incl. sub-types
3 sub-types
- Vaginal adenocarcinoma 7 trials Sub-types →
- Vaginal adenoma 0 trials Sub-types →
- Vaginal mullerian papilloma 0 trials
-
Vulvar glandular neoplasm 0 trials · 5 incl. sub-types
4 sub-types
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Bartholin gland adenoma 0 trials
- Bartholin gland adenomyoma 0 trials
- Minor vestibular glands adenoma 0 trials
-
Villous adenoma 0 trials · 2 incl. sub-types
6 sub-types
- Duodenal villous adenoma 2 trials
- Rectal villous adenoma 0 trials
- Urethral villous adenoma 0 trials
- Urinary bladder villous adenoma 0 trials
- Vaginal villous adenoma 0 trials
- Villous adenoma of colon 0 trials Sub-types →
-
Glandular papilloma 0 trials
2 sub-types
- Paranasal sinus Schneiderian papilloma 0 trials Sub-types →
- Vaginal mullerian papilloma 0 trials
-
Rete ovarii adenoma 0 trials
1 sub-type
- Rete ovarii cystadenoma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 825 trials in this tab.
-
One small incision vs several: robotic stomach cancer surgery put to the test
Cure Not yet recruitingResearchers are comparing two ways of performing robotic surgery to remove stomach cancer: a single-port approach and a standard multi-port approach. The trial enrolls 212 adults with stomach cancer that can be removed with distal gastrectomy. The main question is whether the sin…
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
Cure Not yet recruitingResearchers are testing whether a combination of chemotherapy (mFOLFOX6) plus two immunotherapy drugs, suvemcitug and enlonstobart, can shrink high-risk mid-rectal cancer enough to safely skip pelvic radiation before surgery. The trial enrolls 52 adults with locally advanced rect…
Phase 2 • Sponsor: Fudan University • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a Patient's own immune cells beat advanced kidney cancer?
Cure Not yet recruitingThis early-stage trial is testing an experimental therapy called HS-IT101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. The treatment involves collecting immune cells from the patient's tumor, multiplying them in the lab, and infusing them bac…
Phase 1 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Could a single drug replace surgery for rectal cancer?
Cure Not yet recruitingThis study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
Triple attack on pancreatic tumors: can radiation and immunotherapy make inoperable cancer operable?
Disease control Not yet recruitingResearchers test whether a short course of targeted radiation followed by the immunotherapy drug adebrelimab and NALIRIFOX chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. The trial enrolls 36 adults with previously untreated pancreatic ductal a…
Phase 2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
Disease control Not yet recruitingResearchers are testing whether a liver-sparing form of chemoembolization, called partial TACE, can boost the anti-tumor effects of the drug lenvatinib in people with liver cancer that cannot be removed by surgery. The trial enrolls about 40 adults with hepatocellular carcinoma w…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive missile aims at stubborn kidney tumors
Disease control Not yet recruitingResearchers are testing a radiopharmaceutical called 161Tb-PSMA-1 in adults with metastatic clear cell renal cell carcinoma that has worsened after at least two prior treatments, including immunotherapy and drugs that block blood vessel growth. The trial has two parts: a dose-esc…
Phase 1 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive drug targets Hard-to-Treat thyroid cancer
Disease control Not yet recruitingThis study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …
Phase 1/2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Liver tumors targeted directly: old pump, new drug
Disease control Not yet recruitingThis trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New chemo cocktail targets pancreatic cancer at every stage
Disease control Not yet recruitingResearchers are testing a chemotherapy combination built around albumin-bound paclitaxel (II) for people with pancreatic cancer. The study has three groups: one for advanced cancer that cannot be removed by surgery, one for cancer that may be removable and receives treatment befo…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New vaccine combo aims to halt prostate cancer growth without surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Dual immunotherapy plus chemo before surgery: a new way to shrink stomach tumors?
Disease control Not yet recruitingResearchers are testing whether combining an experimental dual immunotherapy drug called QL1706 with standard chemotherapy (docetaxel, oxaliplatin and S-1) before surgery can help patients with locally advanced gastric or gastroesophageal junction cancer. The study enrolls 34 adu…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Bacteria-Based immunotherapy targets pancreatic tumors in first human test
Disease control Not yet recruitingResearchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…
Phase 1 • Sponsor: Loki Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Old antiparasitic drug joins chemo in pancreatic cancer fight
Disease control Not yet recruitingResearchers at the University of Oklahoma are testing whether adding pentamidine, an antiparasitic drug, to standard modified FOLFIRINOX chemotherapy is safe and helps shrink tumors in people with advanced or metastatic pancreatic cancer. Up to 30 adults with confirmed locally ad…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
Disease control Not yet recruitingResearchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…
Phase 1/2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New injectable drug tested against Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a Phase I trial of HEC-921, an experimental drug given by intravenous infusion, in adults with advanced malignant solid tumors. The study first gives HEC-921 alone to find the highest dose people can tolerate, then tests it in combination with oxaliplatin,…
Phase 1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug put to the test against Hard-to-Treat GI cancers
Disease control Not yet recruitingResearchers are testing an experimental injectable drug called ALK-N001 in adults with advanced gastrointestinal tumors, including esophageal and colorectal cancers that have worsened after standard treatment. The phase II trial gives the drug intravenously every two weeks at one…
Phase 2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Protein-Guided missiles: can mass spectrometry match the right drug to the right tumor?
Disease control Not yet recruitingResearchers are testing whether measuring specific proteins in tumors can help match patients with advanced pancreatic or breast cancer to antibody-drug conjugates that are more likely to work for them. The trial enrolls 225 adults whose cancer has progressed after prior treatmen…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can scans predict which liver cancer patients need extra local therapy?
Disease control Not yet recruitingResearchers are studying whether adding local treatments such as ablation, radiotherapy, or transarterial therapy to the drug combination atezolizumab plus bevacizumab helps certain patients with unresectable hepatocellular carcinoma live longer. The study uses medical records an…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody pair takes aim at advanced liver cancer in major trial
Disease control Not yet recruitingResearchers are testing whether a new combination of two antibodies, JS207 and JS007, works better than the standard first-line treatment of toripalimab plus bevacizumab for advanced liver cancer. The trial enrolls about 560 adults with liver cancer that cannot be removed by surg…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted pill be safely used for RET-Driven cancers in india?
Disease control Not yet recruitingResearchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
Disease control Not yet recruitingResearchers are testing whether a combination of semaglutide (Wegovy), a levonorgestrel-releasing intrauterine device (LNG-IUD), and a structured weight loss program can treat endometrial atypical hyperplasia or early-stage, grade 1 endometrioid endometrial cancer in women who wa…
Phase 2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can immunotherapy plus chemo melt colorectal tumors before surgery?
Disease control Not yet recruitingResearchers are testing whether adding serplulimab, an immunotherapy, to standard CAPOX chemotherapy and bevacizumab can shrink locally advanced colorectal tumors before surgery. The study enrolls about 85 adults with locally advanced rectal adenocarcinoma. The main goal is to se…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can shrinking pancreatic tumors before surgery improve outcomes?
Disease control Not yet recruitingResearchers are testing whether giving chemotherapy before surgery helps people with pancreatic cancer that can be removed. The trial compares two drug combinations, gemcitabine plus nab-paclitaxel and FOLFIRINOX, in adults with resectable pancreatic adenocarcinoma. After treatme…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental combo aims to tackle advanced liver cancer
Disease control Not yet recruitingThis study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…
Phase 1/2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Two-Drug combo targets HER2-Positive stomach cancer after First-Line failure
Disease control Not yet recruitingResearchers are testing whether combining trastuzumab with retlirafusp alfa helps people with HER2-positive gastric or gastroesophageal junction cancer that has worsened after standard first-line treatment. The trial enrolls about 35 adults whose tumors test HER2 2+ or 3+. Partic…
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immune-Drug combo aims to shrink rare kidney tumors before surgery
Disease control Not yet recruitingResearchers are testing two drugs, toripalimab and axitinib, in adults with advanced non-clear cell kidney cancer or renal medullary carcinoma who have not received prior treatment and still have their primary kidney tumor. Everyone receives the drugs for about 12 weeks. Then a t…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can drug cocktail spare rectal cancer patients from surgery?
Disease control Not yet recruitingResearchers test whether giving mFOLFOXIRI plus bevacizumab before surgery can shrink locally advanced rectal cancer enough to avoid removing the rectum. Adults with stage II or III rectal cancer receive six cycles of the drug combination. Depending on how well the tumor responds…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug boost immunotherapy against Hard-to-Treat stomach cancer?
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy combo aims to turn inoperable liver tumors into operable ones
Disease control Not yet recruitingResearchers test whether adding retlirafusp alfa, an experimental immunotherapy, to standard targeted drugs and chemotherapy can shrink colorectal cancer that has spread to the liver enough to allow surgery. The trial enrolls about 80 adults with initially unresectable liver meta…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Triple therapy aims to stall pancreatic cancer
Disease control Not yet recruitingResearchers are testing whether combining retlirafusp alfa, famitinib, and AG chemotherapy (nab-paclitaxel plus gemcitabine) can slow cancer growth in people with unresectable pancreatic cancer. The trial enrolls about 88 adults with locally advanced or metastatic pancreatic duct…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can precision radiation and immunotherapy team up against abdominal colorectal cancer?
Disease control Not yet recruitingResearchers are testing whether adding targeted radiation plus the immunotherapy drug cadonilimab to standard second-line chemotherapy helps adults with colorectal cancer that has spread only to the peritoneum. The trial enrolls about 198 participants and randomly assigns them to…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Saline barrier lets heat target liver tumors near the diaphragm
Disease control Not yet recruitingResearchers are studying whether microwave ablation, helped by a saline injection that separates the liver tumor from the diaphragm, is safe and effective for hepatocellular carcinoma. They compare this approach with surgical resection in patients whose single tumor is 5 cm or sm…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a common cholesterol pill help chemotherapy fight ovarian cancer?
Disease control Not yet recruitingResearchers are studying whether adding daily atorvastatin to standard chemotherapy and surgery changes the immune cells inside advanced high grade serous tumors of the ovary, fallopian tube, or peritoneum. The trial enrolls 40 adults with Stage III or IV disease who cannot have …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Weight-Loss drug meets hormonal IUD in hunt for Surgery-Free cancer care
Disease control Not yet recruitingResearchers are testing whether adding tirzepatide, a weekly drug that treats obesity and diabetes, to a standard levonorgestrel-releasing intrauterine device can help clear early endometrial cancer or a precancerous condition called endometrial intraepithelial neoplasia. The stu…
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New immunotherapy combo put to the test in advanced liver cancer
Disease control Not yet recruitingResearchers are testing whether an experimental immunotherapy called ZG005, combined with bevacizumab, works better than the standard combination of sintilimab and bevacizumab for people with advanced hepatocellular carcinoma who have not yet received systemic treatment. The tria…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Targeted drug 3D185 put to the test against FGFR2-Altered bile duct cancer
Disease control Not yet recruitingResearchers are testing a drug called 3D185 in people with advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, whose tumors have changes in the FGFR2 gene. All participants have already received at least one other systemic cancer treatment that stopped working.…
Phase 2 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to shrink liver tumors in kidney cancer patients
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smart drug outsmart pancreatic cancer?
Disease control Not yet recruitingThis phase III trial tests an experimental drug called YL201 against standard chemotherapy in people with metastatic pancreatic cancer that has progressed after gemcitabine-based treatment. YL201 is designed to deliver a toxin directly to cancer cells that carry a specific marker…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a targeted drug duo boost the power of surgery for stomach cancer?
Disease control Not yet recruitingThis trial tests whether combining two targeted therapies, with or without chemotherapy, can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. Participants receive the treatment before and after surgery to remove the tumor. The main goal is …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can adding immunotherapy to standard cancer care be safe for indian patients?
Disease control Not yet recruitingThis trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…
Phase 4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart pancreatic cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental immunotherapy (SHR-1701) and a targeted drug (apatinib) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with advanced pancreatic cancer. The study enrolls adults aged 18 to 75 who have not yet received trea…
Phase 1/2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can sound waves supercharge immunotherapy against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail targets rare liver cancer in 29-Patient trial
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…
Phase 2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
A Spleen-Saving surgery for pancreatic cancer faces its biggest test
Disease control Not yet recruitingThis trial compares two surgical approaches for people with pancreatic cancer in the left side of the pancreas. One method removes the spleen along with the tumor, which is standard practice. The other preserves the spleen, potentially reducing complications and avoiding lifelong…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThis trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a steroid given during pancreatic surgery prevent a dangerous leak?
Disease control Not yet recruitingThis trial tests whether giving hydrocortisone during and right after pancreatic surgery can lower the risk of a postoperative pancreatic fistula, a serious leak of digestive fluids. About 20 adults with pancreatic, duodenal, or bile duct cancer will be randomly assigned to recei…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug outperform chemotherapy for stomach cancer?
Disease control Not yet recruitingThis trial tests whether an experimental drug called ATG-022 can slow the growth of advanced stomach or gastroesophageal junction cancer better than standard chemotherapy. The study enrolls adults whose tumors show a specific marker called CLDN18.2 and who have already tried at l…
Phase 3 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Pan-RAS inhibitor outsmart pancreatic cancer?
Disease control Not yet recruitingThis trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…
Phase 1/2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted pill shrink hard-to-treat bile duct cancers?
Disease control Not yet recruitingThis phase 2 trial tests whether daraxonrasib, an oral drug that targets cancers with a KRAS mutation, can shrink tumors in people with advanced biliary tract cancer that has progressed after first-line treatment. Participants take the drug once daily in 28-day cycles. The main g…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Smarter radiation planning aims to boost liver tumor attack while sparing healthy tissue
Disease control Not yet recruitingThis study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo may let esophageal cancer patients skip surgery
Disease control Not yet recruitingThis study tests whether giving additional chemotherapy after the usual chemoradiation can better control esophageal cancer and reduce the need for surgery. About 60 adults with stage II to IVA esophageal adenocarcinoma will receive chemoradiation followed by more chemotherapy. T…
Phase 2 • Sponsor: Duke University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
Disease control Not yet recruitingThis study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…
Phase 4 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Anti-Inflammatory drug may boost cancer therapy in bile duct cancer
Disease control Not yet recruitingThis study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker …
Phase 1/2 • Sponsor: Shanghai 6th People's Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can clot removal help even the largest strokes?
Disease control Not yet recruitingThis trial tests whether a procedure to remove blood clots from the brain, called endovascular treatment, can improve recovery in people who have had a severe stroke with a very large area of brain damage. Participants receive either the clot-removal procedure plus standard medic…
Sponsor: First Affiliated Hospital of Harbin Medical University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a daily mineral make liver cancer therapy work better?
Disease control Not yet recruitingThis trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…
Phase 2 • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Ancient herbal mix could boost liver health in advanced cancer
Disease control Not yet recruitingThis trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…
Phase 2 • Sponsor: Xiang-Qian • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a triple drug attack stop liver cancer from coming back?
Disease control Not yet recruitingThis trial tests whether combining three treatment approaches can reduce the chance of liver cancer returning after surgery. People who had their liver cancer completely removed but showed signs of microvascular invasion, a risk factor for recurrence, will receive chemotherapy di…
Phase 4 • Sponsor: Zhai Wenlong • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Immunotherapy combo aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests whether two immunotherapy drugs, cemiplimab and fianlimab, can safely shrink colon tumors before surgery in people with stage II-III colon cancer that hasn't spread. Participants get two IV doses before surgery, then are followed for up to three years. The goal i…
Phase 2 • Sponsor: John Strickler, M.D. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new immunotherapy combo tame aggressive appendiceal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Long-Acting immune booster help fight advanced solid tumours?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental virus therapy takes on Drug-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill outsmart mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…
Phase 1 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Donor cells join fight against advanced cancers
Disease control Not yet recruitingThis early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…
Phase 1/2 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Not yet recruitingThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Pronged immune attack outsmart stomach cancer?
Disease control Not yet recruitingThis Phase 2 trial is testing whether rilvegostomig, an experimental immunotherapy that blocks two immune-suppressing pathways (PD-1 and TIGIT), can produce a stronger immune response against advanced gastric cancer than the standard single-target drug pembrolizumab. About 50 peo…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Weight-loss shot plus IUD may help reverse womb cancer without surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Not yet recruitingThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can immune cells shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…
Phase 1 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
Disease control Not yet recruitingThis study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental vaccine cocktail targets rare liver cancer in early trial
Disease control Not yet recruitingThis early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a targeted drug combo outsmart a common pancreatic cancer mutation?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding another experimental drug (GFS202A or GFH276) to a targeted therapy (GFH375) works better than GFH375 alone in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already had at…
Phase 2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn childhood cancers
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Weight-Loss drug boost Fertility-Sparing cancer treatment?
Disease control Not yet recruitingThis trial tests whether adding mazdutide, a weekly injection that helps with weight loss, to a hormonal intrauterine device (IUD) can improve treatment for overweight or obese women with atypical endometrial hyperplasia or early-stage endometrioid endometrial cancer who wish to …
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a drug combo prime the immune system to fight kidney cancer before surgery?
Disease control Not yet recruitingThis phase II trial is testing whether giving toripalimab (an immunotherapy) plus axitinib (a targeted therapy) for about 12 weeks before a possible delayed kidney removal can help control advanced clear cell kidney cancer. The study enrolls adults whose primary kidney tumor is s…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an Anti-Inflammatory drug make liver cancer immunotherapy safer?
Disease control Not yet recruitingThis phase II trial is testing whether adding tocilizumab, an anti-inflammatory drug, to a standard two-drug immunotherapy regimen can reduce severe immune-related side effects in people with advanced liver cancer. The study enrolls about 51 adults with hepatocellular carcinoma t…
Phase 2 • Sponsor: CHA University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can freezing breast tumors replace the scalpel?
Disease control Not yet recruitingThis trial is investigating whether cryoablation, a technique that freezes and destroys breast tumors with extreme cold, can be an effective alternative to surgery for certain patients. The study will include adults with localized breast cancer who cannot or choose not to have su…
Sponsor: Ospedale Cottolengo • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Smartwatch-Guided prehab aims to boost pancreatic surgery recovery
Disease control Not yet recruitingThis trial tests whether a wearable device and a personalized prehabilitation program can help adults recover better after surgery for pancreatic cancer or related conditions. Participants will wear a monitor to track vital signs and activity, and follow a program of exercise, nu…
Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy keep stomach cancer at bay?
Disease control Not yet recruitingThis trial is testing whether adding the immunotherapy drug serplulimab to a standard chemotherapy regimen (SOX) after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. The study includes adults with stage II-III cancer whose tumors show certa…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new targeted drug boost Chemotherapy's power against pancreatic cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy can help people with pancreatobiliary cancers, including pancreatic ductal adenocarcinoma. Participants will receive either the new combination or standar…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can switching cancer therapy early extend life in stomach cancer?
Disease control Not yet recruitingThis trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tisleli…
Phase 3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can an immunotherapy combo turn inoperable gallbladder cancer into a surgical success?
Disease control Not yet recruitingThis phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …
Phase 2 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can AI-Guided home training boost recovery from gastric cancer surgery?
Disease control Not yet recruitingThis trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can diet and vitamin c supercharge rectal cancer treatment?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding a ketogenic diet and/or high-dose intravenous vitamin C to standard chemoradiotherapy and immunotherapy can improve outcomes for patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR/MSS). The stud…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug combo shrink liver tumors?
Disease control Not yet recruitingThis study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
Disease control Not yet recruitingThis trial tests whether an AI tool called SurgDiff can predict how difficult rectal cancer surgery will be, based on MRI scans and patient data. The goal is to help surgeons choose the best surgical approach for each patient, potentially reducing complications. The study involve…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…
Phase 2 • Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Organ transplant may offer new hope for rare abdominal cancer patients
Disease control Not yet recruitingThis study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Liver cancer trial aims to boost immunotherapy with targeted chemo
Disease control Not yet recruitingThis phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene test may guide smarter chemo for pancreatic cancer
Disease control Not yet recruitingThis phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Action drug combo outsmart advanced liver cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Stomach cancer trial combines chemo and quick radiation to boost remission
Disease control Not yet recruitingThis phase 2 trial tests giving short course radiation therapy along with standard chemotherapy before surgery for stomach cancer. The goal is to see if this total neoadjuvant therapy leads to a higher rate of complete cancer disappearance, with fewer side effects than traditiona…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Two-Drug combo keep fighting a rare ovarian cancer?
Disease control Not yet recruitingThis study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a 'No-Touch' microwave technique match surgery for liver tumors?
Disease control Not yet recruitingThis study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
Disease control Not yet recruitingThis phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
Disease control Not yet recruitingThis phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Drug punch shrink eyelid tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving two drugs—sintilimab and disitamab vedotin—before surgery can shrink tumors in people with a rare type of eyelid cancer called sebaceous gland carcinoma. Participants receive two cycles of the combination, then undergo surgery to remove the tu…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Pronged immune attack shrink kidney tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving a combination of an experimental immunotherapy (epalolitoworelimab) and a targeted therapy (lenvatinib) before and after surgery can improve outcomes for people with high-risk clear cell kidney cancer. The treatment is given first to shrink th…
Phase 2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Triple-Drug cocktail turn inoperable liver cancer into a surgical target?
Disease control Not yet recruitingThis trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
AI-Powered surveillance may outsmart liver cancer recurrence
Disease control Not yet recruitingThis trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
AI takes on liver cancer: could a computer help pick the right immunotherapy?
Disease control Not yet recruitingThis trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can two immune boosters outsmart Chemo-Resistant colon cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding two immune-boosting drugs, iparomlimab and tuvonralimab, to standard chemotherapy can help people with a specific type of metastatic colorectal cancer that has stopped responding to first-line treatment. The study includes about 270 ad…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug targets rare genitourinary cancers in new trial
Disease control Not yet recruitingThis phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with two rare types of cancer: papillary renal carcinoma and less common forms of bladder cancer. The drug is given by IV every two weeks for up to three years. The main goal is to see how many…
Phase 2 • Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Blood test could signal when to switch breast cancer therapy before tumors grow
Disease control Not yet recruitingThis phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Gut bacteria transplant may supercharge liver cancer immunotherapy
Disease control Not yet recruitingThis trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
Disease control Not yet recruitingThis trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Heating the body to fight pancreatic cancer: a new trial tests Whole-Body hyperthermia
Disease control Not yet recruitingThis trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …
Phase 2/3 • Sponsor: ElmediX • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Sound waves take on pancreatic cancer: new trial tests focused ultrasound
Disease control Not yet recruitingThis clinical trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy can help people with borderline resectable or locally advanced pancreatic cancer. The study will enroll 136 adults aged 18-85 with confirmed pancreatic ductal adenocarcinoma. Half will ge…
Sponsor: IMGT Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug hope for rare throat and thyroid cancers
Disease control Not yet recruitingThis study tests a drug called sacituzumab tirumotecan in people with two rare cancers: adenoid cystic carcinoma (a type of salivary gland cancer) and papillary thyroid carcinoma that have returned or spread. About 68 participants will receive the drug through an IV twice a month…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
Disease control Not yet recruitingThis study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …
Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New Dual-Action antibody could extend lives in stomach cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Chemotherapy drug temozolomide under review for tough pituitary tumors
Disease control Not yet recruitingThis study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…
Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Radiation may spare early rectal cancer patients from radical surgery
Disease control Not yet recruitingThis observational study follows about 196 adults with early-stage (pT1) rectal cancer who have high-risk features after local tumor removal. Instead of undergoing radical surgery that often requires a colostomy, participants receive adjuvant radiotherapy or chemoradiotherapy. Th…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a $4 statin improve cancer survival?
Disease control Not yet recruitingThis phase II trial tests whether adding simvastatin, a widely used cholesterol medication, to standard chemotherapy (with or without immunotherapy) can improve outcomes for people with gastroesophageal adenocarcinoma. About 184 patients will be randomly assigned to receive eithe…
Phase 2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Simple blood tests could spot liver cancer earlier in diabetics
Disease control Not yet recruitingThis study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Custom-Made vaccine aims to boost immune attack on kidney tumors
Disease control Not yet recruitingThis early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recogniz…
Phase 1 • Sponsor: Jian Lin • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New targeted pill holds promise for rare salivary gland cancer that spreads
Disease control Not yet recruitingThis phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Pre-Surgery cocktail aims to boost liver cancer outcomes
Disease control Not yet recruitingThis study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then und…
Phase 2 • Sponsor: Affiliated Hospital of Guangdong Medical University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults wi…
Phase 1/2 • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could an asthma drug help fight lung cancer? early trial investigates
Disease control Not yet recruitingThis pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…
Phase 1 • Sponsor: Carcinex Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to boost surgery success in colon cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receiv…
Phase 2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Short-Course radiation may boost immunotherapy and chemo for stomach cancer
Disease control Not yet recruitingThis study investigates whether adding a short course of radiotherapy before surgery, alongside a PD-1 inhibitor (serplulimab) and chemotherapy (SOX), can improve outcomes for people with locally advanced upper stomach or gastroesophageal junction cancer. Participants are randoml…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control Not yet recruitingThis phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tackle deadly pancreatic cancer
Disease control Not yet recruitingThis study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…
Phase 1/2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a single day of radiation replace weeks of treatment for breast cancer?
Disease control Not yet recruitingThe SASHA trial is testing whether a single, high-dose radiation treatment delivered directly to the tumor site over one day is safe and effective for women with early-stage breast cancer. The study will enroll 134 women aged 40-85 who have already had a lumpectomy. Researchers w…
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to shrink rectal tumors and save organs
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs to radiation therapy can better shrink advanced rectal cancer than standard chemoradiation. About 342 adults with a specific type of rectal cancer will be randomly assigned to one of three treatment groups. The goal is to se…
Phase 2/3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo without chemotherapy aims to shrink rectal tumors before surgery
Disease control Not yet recruitingThis small study tests a new approach for people with stage II/III rectal cancer that has not spread. Instead of chemotherapy, patients receive targeted internal radiation followed by two doses of the immunotherapy drug nivolumab before surgery. The goal is to see if this combina…
Phase 2 • Sponsor: Dr. Te Vuong • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Can weight-loss drugs and hormones make endometrial cancer surgery safer for obese women?
Disease control Not yet recruitingThis study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…
Phase 4 • Sponsor: Hospital Universitari de Bellvitge • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy cocktail aims to turn untreatable stomach tumors into surgical targets
Disease control Not yet recruitingThis phase 2 trial tests whether combining two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) can shrink locally advanced stomach cancer that cannot be surgically removed. The goal is to make the tumors small enough for surgery. The study enrol…
Phase 2 • Sponsor: Chen Lizhu • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Genetic test may guide chemo choice for pancreatic cancer patients
Disease control Not yet recruitingThis phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…
Phase 2 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Blood test could spare stomach cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study tests whether a simple blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery. About 304 people with locally advanced stomach cancer will be randomly assigned to either standard…
Phase 3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail aims to boost kidney cancer surgery success
Disease control Not yet recruitingThis Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Oxygen-Boosting injection may help rectal cancer patients avoid surgery
Disease control Not yet recruitingThis study tests whether injecting a special solution (KRC-01) into rectal tumors before radiation can make the radiation work better. The solution increases oxygen inside the tumor, which helps radiation kill cancer cells. About 24 adults with advanced rectal cancer that hasn't …
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising drug cocktail aims to shrink aggressive nasal tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of anlotinib (a targeted therapy) and epirubicin (chemotherapy) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma, a rare and aggressive cancer of the nasal cavity and sinuses. About 76 pa…
Phase 2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a food additive help fight stomach cancer? new trial explores
Disease control Not yet recruitingThis study tests whether adding sodium propionate, a common food preservative, to standard immunotherapy and chemotherapy can improve tumor shrinkage in people with advanced stomach cancer. About 20 adults with inoperable gastric cancer will be randomly assigned to receive either…
Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New triple therapy targets stomach cancer after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors …
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for liver cancer patients when immunotherapy stops working
Disease control Not yet recruitingThis phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Liver-Focused chemo after surgery aims to stop cancer return
Disease control Not yet recruitingThis Phase 3 trial tests whether giving chemotherapy directly into the liver artery (HAI) after surgery can prevent cancer from coming back in patients with colorectal cancer that spread to the liver. About 272 high-risk patients will receive either standard IV chemo or HAI chemo…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to shrink advanced stomach tumors
Disease control Not yet recruitingThis study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo aims to shrink tough colon cancers before surgery
Disease control Not yet recruitingThis phase II trial tests whether a stronger chemotherapy cocktail (cmFOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) when given before surgery for locally advanced colon cancer. About 138 patients with high-risk stage II …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a diabetes shot help beat uterine cancer without surgery?
Disease control Not yet recruitingThis study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Freeze-and-Heat attack: could a new device boost liver cancer treatment?
Disease control Not yet recruitingThis study tests whether adding a special thermal therapy (which freezes and heats tumors) to standard targeted therapy and immunotherapy can help people with advanced liver cancer that cannot be removed by surgery. About 166 participants will be randomly assigned to receive eith…
Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Nutritional boost before colorectal surgery may cut complications
Disease control Not yet recruitingThis study tests whether giving patients special nutritional drinks and a tailored diet before and after colorectal cancer surgery can lower the risk of complications like infections and improve recovery. About 190 adults with colorectal cancer who are scheduled for minimally inv…
Sponsor: Istituto Clinico Humanitas • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to shrink kidney tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Vitamin d trial aims to strengthen immune system in black men with prostate cancer
Disease control Not yet recruitingThis phase 3 trial tests whether daily vitamin D supplements can improve immune function and quality of life in Black/West African men with prostate cancer who have low vitamin D levels. Researchers will compare men with localized disease to those with advanced cancer, tracking i…
Phase 3 • Sponsor: University of Ilorin Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThis phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long…
Phase 2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New personalized vaccine takes on tough cancers
Disease control Not yet recruitingThis early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…
Phase 1 • Sponsor: Centre Georges Francois Leclerc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for pancreatic cancer: combo therapy enters phase 2 trial
Disease control Not yet recruitingThis study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemo…
Phase 2 • Sponsor: Nelum Corp • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immune cells Tailor-Made to attack pancreatic cancer enter first human test
Disease control Not yet recruitingThis early-stage trial tests a new therapy called MT-601, which uses a patient's own immune T-cells trained to recognize multiple cancer-related targets. It is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study will check safety …
Phase 1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could blood pressure pills boost stomach cancer treatment?
Disease control Not yet recruitingThis study looks at whether adding a common blood pressure medication (beta-blocker) to standard immunotherapy can help shrink stomach cancer before surgery. It will include 33 adults with high blood pressure and locally advanced stomach cancer. The goal is to see if the combinat…
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Radiation-Free hope: study tests if surgery alone is enough for rare nasal cancer
Disease control Not yet recruitingThis study looks at whether patients with a rare nasal cancer (sinonasal adenoid cystic carcinoma) can safely avoid radiation after surgery if the tumor was completely removed. About 200 patients will choose either surgery alone or surgery plus radiation, and researchers will tra…
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New trial aims to save rectums in early cancer patients
Disease control Not yet recruitingThis study looks at whether adding a short course of chemotherapy after standard chemoradiation can improve outcomes for people with stage I rectal cancer, allowing them to keep their rectum instead of needing major surgery. About 292 participants will be randomly assigned to rec…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Thyroid cancer surgery debate: to dissect or not to dissect neck nodes?
Disease control Not yet recruitingThis study looks at people with papillary thyroid cancer tumors 2 to 4 cm who are having thyroid surgery. Half will also have nearby neck lymph nodes removed, and half will not. The goal is to see if removing these nodes lowers the chance of cancer coming back or persisting, and …
Sponsor: Leonardo Rossi • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo radiation therapy aims to spare elderly rectal cancer patients from surgery
Disease control Not yet recruitingThis study tests a combination of two types of radiation therapy for elderly or frail patients with rectal cancer who cannot or will not have surgery. The goal is to shrink or control the tumor while maintaining quality of life. Researchers will follow 80 participants for up to t…
Sponsor: University Hospital of Cologne • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Virus cocktail takes on tough liver tumors
Disease control Not yet recruitingThis phase 2 trial tests whether injecting an oncolytic virus (H101) directly into liver tumors, along with radiation, chemotherapy, targeted therapy, and immunotherapy, can shrink or control colorectal cancer that has spread to the liver and cannot be removed by surgery. The stu…
Phase 2 • Sponsor: Jun Huang • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New biosimilar aims to offer cheaper option for colorectal cancer
Disease control Not yet recruitingThis Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…
Phase 1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New surgical order may boost pancreatic cancer outcomes
Disease control Not yet recruitingThis study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New keyhole breast cancer surgery could offer better looks, same safety
Disease control Not yet recruitingThis study tests a new type of breast-conserving surgery that uses a small camera inserted through a hidden armpit incision to remove tumors, compared to the standard open approach. About 1,366 women with early-stage breast cancer will be randomly assigned to one of the two surge…
Sponsor: Du Zhenggui • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Smarter radiation aims to cut side effects in prostate cancer relapse
Disease control Not yet recruitingThis study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to active cancer spots and lower doses to healthy areas, all in just 5 treatments over two weeks. The goal i…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Second-line hope: regorafenib tested after lenvatinib failure in liver cancer
Disease control Not yet recruitingThis study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal…
Phase 2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for liver cancer patients with liver damage: drug tested after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progr…
Phase 2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for tough stomach cancer: triple drug attack
Disease control Not yet recruitingThis study tests a combination of three drugs (disitamab vedotin, tunlametinib, and a PD-1 antibody) in people with advanced stomach cancer that has a specific protein (HER2) and has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy aims to slash liver cancer recurrence after surgery
Disease control Not yet recruitingThis study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug duo aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis early-phase trial tests whether adding two targeted drugs (zanidatamab and tislelizumab) to standard chemotherapy can completely eliminate HER2-positive gastroesophageal cancer before surgery. About 29 adults with operable, locally advanced disease will receive the combinati…
Phase 1/2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Breakthrough study aims to spare rectal cancer patients from surgery
Disease control Not yet recruitingThis study tests whether a targeted chemoradiotherapy can completely eliminate early-stage rectal cancer, allowing patients to avoid surgery and keep their rectum. 90 adults with small, localized tumors will either receive standard surgery or the new treatment followed by close m…
Phase 4 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Targeted chemo delivery aims to boost pancreatic cancer surgery success
Disease control Not yet recruitingThis early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…
Phase 1/2 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New study tracks heat therapy for kidney tumors
Disease control Not yet recruitingThis study watches 226 adults with small kidney tumors (stage T1a) who get radiofrequency ablation, a treatment that uses heat to destroy cancer cells. Researchers will track how well the procedure works and any side effects. No extra treatments or tests are given—just normal car…
Sponsor: Humanitas Hospital, Italy • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Migraine drug takes on pancreatic cancer in early trial
Disease control Not yet recruitingThis early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays und…
Phase 1/2 • Sponsor: Xiuchao Wang • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Robot vs. laparoscope: which surgery is safer for early stomach cancer?
Disease control Not yet recruitingThis study compares two types of minimally invasive surgery for early-stage stomach cancer: a newer robotic method using fewer incisions (reduced-port) and the standard laparoscopic method. About 538 patients will be randomly assigned to one of the two surgeries. The main goal is…
Phase 4 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New Low-Cost radiation therapy could make liver cancer treatment accessible for all
Disease control Not yet recruitingThis study tests a new, affordable type of radioactive microsphere for treating liver cancer that cannot be removed by surgery. The microspheres are delivered directly to the tumor through a blood vessel, delivering radiation to kill cancer cells. The trial will enroll 18 adults …
Phase 1 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to make inoperable bile duct cancer eligible for transplant
Disease control Not yet recruitingThis phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that can…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to fight advanced colorectal cancer
Disease control Not yet recruitingThis phase II trial tests whether a special radiotherapy regimen followed by targeted therapy and immunotherapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatments. About 33 participants will receive the treatment and be monitore…
Phase 2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo tackles kidney cancer that came back after immunotherapy
Disease control Not yet recruitingThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer gr…
Phase 2 • Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for bile duct cancer: combo therapy aims to boost survival
Disease control Not yet recruitingThis study tests whether adding the drug Mitazalimab to standard chemotherapy helps people with advanced bile duct cancer live longer. About 160 adults whose cancer has spread or cannot be removed will receive either chemo alone or chemo plus Mitazalimab. Researchers will check s…
Phase 2/3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail therapy aims to tackle Drug-Resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted ther…
Phase 2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could amino acids boost liver cancer treatment?
Disease control Not yet recruitingThis phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New study tests if All-Keyhole surgery beats hybrid approach for esophageal cancer
Disease control Not yet recruitingThis phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Liver cancer breakthrough? study tests surgery vs. drug maintenance after successful initial therapy
Disease control Not yet recruitingThis study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Radiation plus immunotherapy: a new hope for rectal cancer patients?
Disease control Not yet recruitingThis phase 2 trial is testing a new approach for people with stage II-III rectal cancer. It combines short-course radiotherapy that spares the tumor-draining lymph nodes with a PD-1 inhibitor (a type of immunotherapy). The goal is to see if this combination can lead to a complete…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for stomach cancer: drug combo aims to wipe out tumors before surgery
Disease control Not yet recruitingThis study tests whether adding the drug ivonescimab to standard chemotherapy (SOX) can better shrink or eliminate tumors in people with locally advanced stomach or gastroesophageal junction cancer before surgery. About 154 adults aged 18-75 will be randomly assigned to receive e…
Phase 2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Blue dye could make thyroid cancer surgery safer and more precise
Disease control Not yet recruitingThis study tests whether injecting a blue dye called mitoxantrone hydrochloride into the thyroid during robotic surgery helps surgeons see and remove cancer-affected lymph nodes while avoiding the parathyroid glands. 114 people with papillary thyroid cancer will be randomly assig…
Phase 4 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New trial matches liver cancer treatment to Tumor's Fat-Burning signature
Disease control Not yet recruitingThis phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …
Phase 2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Blocking blood flow before surgery may help remove inoperable bile duct cancer
Disease control Not yet recruitingThis study tests whether blocking the artery that feeds a bile duct tumor before surgery can make it possible to remove the cancer safely. It includes 33 adults with advanced bile duct cancer that currently cannot be operated on. The main goal is to see how many patients are aliv…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental cocktail takes on toughest pancreatic cancer
Disease control Not yet recruitingThis early-stage trial tests whether adding ATRA, SDK002, and an immunotherapy drug to standard chemotherapy is safe for people with advanced pancreatic cancer that cannot be removed by surgery. Ten participants will receive all five drugs together. The study will also track how …
Phase 1 • Sponsor: Daniel Breadner • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for advanced liver cancer: drug trial targets patients with limited options
Disease control Not yet recruitingThis phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…
Phase 2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for stomach cancer: immunotherapy combo targets resistant tumors
Disease control Not yet recruitingThis phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug elranatamab tested in Real-World chinese myeloma patients
Disease control Not yet recruitingThis study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis Phase 3 trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy (SOX) can improve outcomes for people with locally advanced stomach cancer that cannot be removed right away. The study will enroll 118 participa…
Phase 3 • Sponsor: Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cocktail of pills plus procedure aims to fight untreatable liver cancer
Disease control Not yet recruitingThis study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly a…
Phase 2/3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New, less invasive surgery for early stomach cancer shows promise in small trial
Disease control Not yet recruitingThis study tests a less invasive surgical approach for people with early gastric cancer who need additional treatment after an initial endoscopic removal. The procedure uses a special dye to guide removal of nearby lymph nodes, with or without removing a small part of the stomach…
Sponsor: Region Stockholm • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Robot-Guided radiation aims to shrink kidney tumors with fewer side effects
Disease control Not yet recruitingThis study tests a highly precise type of radiation called SBRT for people with kidney cancer who cannot undergo surgery. The treatment uses a robotic system (CyberKnife) to deliver high-dose radiation directly to the tumor while sparing healthy tissue. Researchers will track 60 …
Sponsor: IRCCS San Raffaele • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Blood sugar control may boost chemo survival in pancreatic cancer patients
Disease control Not yet recruitingThis study looks at whether actively treating diabetes with drugs like metformin or insulin can help people with metastatic pancreatic cancer live longer when they also receive standard chemotherapy. About 210 adults with both pancreatic cancer and diabetes will be enrolled. The …
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising new drug cocktail targets tough pancreatic cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding nimotuzumab, a targeted antibody, to standard chemotherapy can help people with high-risk pancreatic cancer that can still be surgically removed. About 156 participants will receive either the drug combo or a placebo before and after surger…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could surgery after hormone therapy beat advanced prostate cancer?
Disease control Not yet recruitingThis study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Timing is everything: new trial tests surgery before or after immunotherapy for kidney cancer
Disease control Not yet recruitingThis clinical trial is for adults with metastatic clear cell kidney cancer. It compares having surgery to remove the kidney tumor either before or after starting immunotherapy drugs (ipilimumab and nivolumab). The goal is to see which timing helps people live longer without the c…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Shorter radiation may be just as good for rectal cancer patients
Disease control Not yet recruitingThis study compares two standard radiotherapy approaches—short-course (1 week) and long-course (several weeks)—given before surgery to people with locally advanced rectal cancer. The goal is to see which one works better at shrinking tumors and is easier for patients to tolerate.…
Sponsor: Rajiv Gandhi Cancer Institute & Research Center, India • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Blood test may spare gastric cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study tests whether a simple blood test that detects tiny traces of cancer DNA can guide treatment decisions after gastric cancer surgery. About 90 patients will have their blood tested after surgery, and those with no detectable cancer DNA may safely skip additional chemoth…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Surgery-free breast cancer treatment tested in new trial
Disease control Not yet recruitingThis study is testing whether people with certain non-invasive or early breast conditions (like ductal carcinoma in situ) can safely skip surgery and instead take hormone-blocking medication. The goal is to see if this approach keeps cancer from coming back over five years. The t…
Sponsor: Jeong Eon Lee • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Zapping liver cancer: electric pulses target tumors, spare healthy tissue
Disease control Not yet recruitingThis study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to se…
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo aims to wipe out High-Risk rectal cancer before surgery
Disease control Not yet recruitingThis study is testing whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation can better shrink or eliminate tumors in people with locally advanced rectal cancer that has a high chance of coming back. About 30 participants will receive the combination tre…
Phase 2 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Electric pulses zapping liver tumors: new hope for colorectal cancer patients?
Disease control Not yet recruitingThis study tests a procedure called irreversible electroporation (IRE), also known as Nanoknife, to treat liver tumors that have spread from colorectal cancer. IRE uses short electrical pulses to destroy cancer cells while sparing nearby blood vessels and bile ducts. The trial wi…
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to turn inoperable pancreatic cancer into operable tumors
Disease control Not yet recruitingThis study tests whether a specific sequence of two different chemotherapy combinations, each paired with an immunotherapy drug (PD-L1 antibody), can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgical removal. About 77 adults with this typ…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug before prostate surgery aims to wipe out hidden cancer cells
Disease control Not yet recruitingThis study looks at giving the drug rezvilutamide to men with high-risk or locally advanced prostate cancer before their surgery. The goal is to see if it can completely clear cancer cells from the removed tissue and reduce the chance of the cancer coming back. About 115 particip…
Sponsor: Shanghai Pudong New Area Gongli Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Liver cancer breakthrough: surgery or pills after shrinkage?
Disease control Not yet recruitingThis study looks at patients with advanced liver cancer that cannot be removed by surgery at first. They receive a combination of treatments—chemotherapy directly into the liver, anti-angiogenic drugs, and immunotherapy—to shrink the tumor. If the tumor shrinks enough to become r…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Boosting radiation may help more rectal cancer patients reach remission
Disease control Not yet recruitingThis study tests whether a higher dose of radiation (58.75 Gy) given before surgery can help more people with locally advanced rectal cancer achieve a complete response (no cancer left) compared to the standard dose (50 Gy). About 156 adults aged 18-79 will receive radiation plus…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase 1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to shrink rectal tumors with fewer side effects
Disease control Not yet recruitingThis phase 2 trial tests a new approach for locally advanced rectal cancer: using MRI-guided, reduced-field short-course radiotherapy together with immunotherapy and chemotherapy before surgery. The goal is to shrink the tumor effectively while causing fewer side effects than sta…
Phase 2 • Sponsor: Longhao Li • Aim: Disease control
Last updated Jun 26, 2026 16:55 UTC
-
Less may be more: smaller lung surgery tested against standard removal
Disease control Not yet recruitingThis study compares two types of surgery for people with a specific kind of lung cancer (adenocarcinoma) that is 2-3 cm in size and has a low-to-intermediate grade. One surgery removes just the part of the lung with the tumor (segmentectomy), while the other removes an entire lob…
Phase 3 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New trial aims to improve survival for a tough pancreatic cancer
Disease control Not yet recruitingThis phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/…
Phase 3 • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:50 UTC
-
Could a quick radiation shot keep prostate cancer in check without surgery?
Disease control Not yet recruitingThis study compares a precise, focused radiation treatment (stereotactic body radiotherapy) to simply watching the cancer (active surveillance) in men with low-to-intermediate risk prostate cancer. The goal is to see if the radiation can reduce the number of men who later need st…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Liege • Aim: Disease control
Last updated Jun 26, 2026 12:52 UTC
-
New hope for liver cancer: drug targets tumors resistant to immunotherapy
Disease control Not yet recruitingThis phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers tha…
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 26, 2026 12:37 UTC
-
New drug cocktail aims to fight tough bile duct cancer
Disease control Not yet recruitingThis study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangi…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 12:36 UTC
-
Engineered immune cells take on pancreatic cancer in first human trial
Disease control Not yet recruitingThis early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study ai…
Phase 1/2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 26, 2026 12:34 UTC
-
Mapping the DNA test that decides who gets PARP inhibitors
Diagnosis Not yet recruitingResearchers are reviewing medical records from about 1,125 women in Italy with newly diagnosed advanced high-grade epithelial ovarian cancer. The study focuses on how hospitals test tumors for homologous recombination deficiency (HRD), a DNA repair flaw that can make PARP inhibit…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a simple blood test spot pancreatic cancer early enough to save lives?
Diagnosis Not yet recruitingThis registry study follows 400 people at increased risk for pancreatic ductal adenocarcinoma who receive PancreaSure, a blood test designed to detect early-stage disease. Researchers track whether the test results lead doctors to change surveillance plans, such as scheduling mor…
Sponsor: Immunovia, Inc. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a new tracer reveal hidden tumors?
Diagnosis Not yet recruitingThis trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …
Early phase 1 • Sponsor: Lumina Pharmaceuticals Inc • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
Blood test may foretell immunotherapy outcomes in rare kidney cancer
Diagnosis Not yet recruitingThis study is testing whether a personalized blood test can predict how well immunotherapy works in people with advanced non-clear cell kidney cancer. The test looks for tiny pieces of tumor DNA in the blood, called circulating tumor DNA (ctDNA), before and during treatment. Rese…
Sponsor: West China Hospital • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Can a single injection reveal hidden kidney cancer?
Diagnosis Not yet recruitingThis early-stage trial tests an experimental imaging agent called 68Ga-NYM096 in 20 adults who have a kidney mass of uncertain nature seen on CT or MRI and are scheduled for surgery. The agent is designed to attach to a protein common on clear cell renal cell carcinoma cells, pot…
Phase 1 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
Can AI be a second pair of eyes for liver cancer detection?
Diagnosis Not yet recruitingThis trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…
Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
A sharper eye on prostate cancer: could new imaging spare healthy tissue?
Diagnosis Not yet recruitingThis pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Can a simple MRI and blood test catch pancreatic cancer earlier?
Diagnosis Not yet recruitingThis pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to u…
Sponsor: Saskia Hendrich • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New PET scan could spot hidden kidney cancer after treatment
Diagnosis Not yet recruitingThis study tests whether a special PET scan using a drug called 89Zr-girentuximab can detect kidney cancer that remains or comes back after initial treatment. Ten adults with clear cell renal cell carcinoma will receive the drug and then have a PET scan. Some will also have a sec…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
New ultrasound technique could reveal hidden blood vessels in liver tumors
Diagnosis Not yet recruitingThis study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …
Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingThis study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Glowing dye could reveal invisible cancer clues in the esophagus
Diagnosis Not yet recruitingThis study tests whether a fluorescent tracer called WGA-800CW can make precancerous or cancerous cells in Barrett's esophagus glow during endoscopy. The tracer is sprayed onto the esophagus, and special cameras detect the glow. The goal is to find the best dose and see if this m…
Phase 1 • Sponsor: University Medical Center Groningen • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New scope may spot bile duct cancer faster
Diagnosis Not yet recruitingThis study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.
Sponsor: David KARSENTI • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New imaging agent could improve detection of rare cancers
Diagnosis Not yet recruitingThis study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New scan aims to spot liver cancer more clearly
Diagnosis Not yet recruitingThis study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New scan may better spot hidden cancer in lymph nodes
Diagnosis Not yet recruitingThis study will compare two different PET/MRI scans to see which one is better at finding lymph node metastases in people with middle to high rectal cancer. Thirty participants will receive both types of scans before surgery. The goal is to see if the newer tracer, [68Ga]Ga-CTR-F…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New laser probe could spot stomach cancer earlier than biopsy
Diagnosis Not yet recruitingThis study looks at whether a special microscope on a thin probe (pCLE) can better detect early stomach cancer than the usual biopsy method. Researchers will review past cases from 169 patients who had both tests. The goal is to see which method is more sensitive and accurate, wh…
Sponsor: Changhai Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New scanner aims to measure breast tumors more accurately
Diagnosis Not yet recruitingThis study will test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately measure the size of breast tumors in people with ductal carcinoma in situ (DCIS). Twelve participants will receive both a standard MRI and an FCI scan before surgery. The results…
Sponsor: University of Aberdeen • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New blood test aims to catch liver cancer recurrence early
Diagnosis Not yet recruitingThis study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…
Sponsor: Tongji Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New scan may tell how aggressive your kidney tumor is
Diagnosis Not yet recruitingThis study tests whether a special PET scan using 82-Rb can tell how aggressive a kidney tumor is. Doctors will compare the scan results to the actual tumor grade after surgery. If it works, patients might avoid unnecessary biopsies or surgeries. The study involves 50 adults with…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New scan could catch breast cancer spread that standard tests miss
Diagnosis Not yet recruitingThis study tests a new type of PET scan using a tracer called 68Ga-FAPI-46 to find cancer that has spread in patients with lobular breast cancer. Standard scans often miss these metastases. The trial will enroll 45 adults whose standard PET scan was negative or unclear, and see i…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Could a simple breath test catch stomach cancer early?
Diagnosis Not yet recruitingThis study tests a new breath test to detect cancers of the stomach and esophagus. Participants provide a breath sample before and after drinking a special liquid. The test looks for chemicals in the breath that may signal cancer. The goal is to see if the drink makes these chemi…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
New blood test aims to predict which cancer patients will benefit from immunotherapy
Diagnosis Not yet recruitingThis study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…
Sponsor: OncoHost Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Liver protein TREM-1 may predict steroid response in alcoholic hepatitis
Diagnosis Not yet recruitingThis study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver disease…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 26, 2026 18:14 UTC
-
Could a nasal tube replace a temporary ileostomy after rectal cancer surgery?
Prevention Not yet recruitingResearchers are testing whether a nasal catheter that diverts stool from the small intestine can prevent leaks after surgery for mid to low rectal cancer. The trial compares this catheter approach with a standard protective ileostomy, a temporary opening in the abdomen to divert …
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Ancient acupoint therapy may speed bowel recovery after liver surgery
Prevention Not yet recruitingThis trial tests whether stimulating specific acupoints—using herbal patches or mild electrical pulses—can help the bowels recover more quickly after liver cancer surgery. Patients scheduled for partial liver removal will be randomly assigned to one of four groups: herbal patches…
Sponsor: Shanghai Zhongshan Hospital • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Low-Dose erlotinib aims to stop liver cancer before it starts
Prevention Not yet recruitingThis phase II trial tests whether a low dose of the cancer drug erlotinib can prevent liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants will take either erlotinib or a placebo daily for a set period. The study will measure changes in a blood protei…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Daily aspirin may slash liver cancer risk in cirrhosis patients
Prevention Not yet recruitingThis study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check…
Phase 3 • Sponsor: Curtin University • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Natural compound SAMe tested to block liver cancer in High-Risk patients
Prevention Not yet recruitingThis study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…
Phase 2 • Sponsor: Cedars-Sinai Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Could a 'Baby Dose' of hormone pills prevent breast cancer?
Prevention Not yet recruitingThis study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
New Two-Step surgery could spare High-Risk women from early menopause
Prevention Not yet recruitingThis study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ov…
Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Can a phone app help pancreatic cancer patients eat better during treatment?
Symptom relief Not yet recruitingResearchers are testing whether a digital nutrition app called STRONG, paired with remote dietitian counseling, is practical and helpful for adults with pancreatic ductal adenocarcinoma who are starting chemotherapy or radiation. About 80 participants join the study and are assig…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a Dietitian's plan help older pancreatic cancer patients feel better?
Symptom relief Not yet recruitingResearchers are testing whether personalised nutritional care from a trained dietitian improves quality of life for people aged 65 and older with pancreatic ductal adenocarcinoma. About 250 participants will be randomly assigned to either six months of individualised nutrition su…
Sponsor: Inna Chen, MD • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Donor nerve grafts put to the test for restoring feeling after mastectomy
Symptom relief Not yet recruitingThis trial tests whether adding a donor nerve graft during implant-based breast reconstruction helps women regain breast and nipple sensation after nipple-sparing mastectomy. Each participant has one breast randomly chosen to receive the graft, while the other breast serves as a …
Phase 4 • Sponsor: Endeavor Health • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a spinal pump deliver better pain relief for pancreatic cancer?
Symptom relief Not yet recruitingThis pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…
Sponsor: Clinique Bizet • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Talking about sex after cancer: telehealth therapy may improve recovery
Symptom relief Not yet recruitingThis study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
AI assistant aims to ease thyroid cancer anxiety before surgery
Symptom relief Not yet recruitingThis study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meet…
Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Estrogen patch may ease hot flashes in prostate cancer treatment
Symptom relief Not yet recruitingThis study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
Symptom relief Not yet recruitingThis trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Gut bacteria may shield nerves from chemo damage – a trial puts it to the test
Symptom relief Not yet recruitingThis phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take e…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Zapping nerves with radiation may ease pancreatic cancer pain
Symptom relief Not yet recruitingThis trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …
Phase 2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New stent technique may lower infection risk in bile duct cancer patients
Symptom relief Not yet recruitingThis study compares two ways to drain blocked bile ducts in people with cancer near the liver. One method places a tube across the blockage into the intestine, while the other uses a metal stent that stops short of the intestine. The goal is to see which approach causes fewer com…
Sponsor: Hospital de Clinicas de Porto Alegre • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Remote workouts aim to restore strength in cancer survivors
Symptom relief Not yet recruitingThis study tests whether a personalized, supervised exercise program done at home can improve physical function in people who have finished treatment for gastroesophageal cancer. About 20 survivors will receive tailored aerobic and resistance exercises via video calls. The goal i…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New surgery could save the areola even when nipple cancer is found
Symptom relief Not yet recruitingThis study tests a new surgical approach for women with early breast cancer who need a nipple-sparing mastectomy. If cancer is found in the nipple during surgery, doctors will remove the nipple but try to save the pigmented skin around it (the areola) and rebuild a new nipple rig…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New scanner could halve repeat breast cancer surgeries
Symptom relief Not yet recruitingThis study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scann…
Sponsor: Hôpital du Valais • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New online tool aims to ease Cancer's toll on patients and loved ones
Symptom relief Not yet recruitingThis study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…
Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Prostate cancer Treatment's hidden cost: study tracks sexual side effects
Symptom relief Not yet recruitingThis study follows 130 men with unfavorable intermediate-risk prostate cancer to see how a combination of targeted radiation (SBRT) and 6 months of hormone therapy (ADT) impacts their sexual function. Researchers measure erectile function before treatment and again after 24 month…
Sponsor: CancerCare Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pumping iron against cancer: exercise may ease treatment side effects
Symptom relief Not yet recruitingThis study tests whether a supervised strength-training program is safe and practical for people with locally advanced rectal cancer who are receiving chemotherapy and radiation before surgery. Fifteen participants will do personalized resistance exercises twice a week for about …
Sponsor: Fundacion Arturo Lopez Perez • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Gut bacteria may help pancreatic surgery recovery
Symptom relief Not yet recruitingThis study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Chlorophyll-Based supplement may ease radiation damage in cervical cancer patients
Symptom relief Not yet recruitingThis phase 3 trial tests whether a daily dose of sodium-copper-chlorophyllin, a chlorophyll derivative, can reduce long-term bladder and bowel side effects from radiation therapy in 316 women with locally advanced cervical cancer. Participants take the supplement for 3 months aft…
Phase 3 • Sponsor: Tata Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New camera mode may speed up gut cancer surgery
Symptom relief Not yet recruitingThis study tests whether a special imaging mode called RDI helps doctors remove early-stage cancers from the stomach, esophagus, or colon more quickly and safely than standard white-light endoscopy. About 158 adults with early cancers or precancerous lesions will be randomly assi…
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Could a cancer drug also fight wasting? tiny trial aims to find out
Symptom relief Not yet recruitingThis early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…
Early phase 1 • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New stent placement method could reduce repeat procedures for bile duct cancer patients
Symptom relief Not yet recruitingThis trial tests a new way to place plastic stents in the bile duct for people with jaundice caused by cancer near the liver. The standard method places the stent across the bile duct opening, while the new method places it above the opening without cutting the muscle. The study …
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Turmeric power: could curcumin ease chemo side effects for rectal cancer patients?
Symptom relief Not yet recruitingThis study tests a highly absorbable form of curcumin (from turmeric) in 72 adults with mid-to-low rectal cancer who are getting chemoradiation before surgery. The goal is to see if curcumin can reduce severe gut side effects like diarrhea and rectal pain. Researchers will also c…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Robot-Assisted mastectomy: could it mean less pain and faster healing?
Symptom relief Not yet recruitingThis study compares two types of nipple-sparing mastectomy: one done with a robotic arm through a small side incision, and the standard open surgery. Researchers want to see if the robotic method improves women's satisfaction, body image, and recovery over 12 months. The trial wi…
Sponsor: Beaumont Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Prostate cancer study aims to find gentler radiation option
Symptom relief Not yet recruitingThis study compares the side effects of two radiation treatments for men with low-to-intermediate risk prostate cancer: low dose rate brachytherapy (radioactive seeds placed in the prostate) and ultra-hypofractionated radiotherapy (5 sessions of external radiation over 2 weeks). …
Sponsor: Royal Surrey County Hospital NHS Foundation Trust • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Herbal pill may ease cancer treatment burden
Symptom relief Not yet recruitingThis study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 26, 2026 16:24 UTC
-
Can Real-World data reveal the best rectal cancer treatment?
Knowledge-focused Not yet recruitingThis observational study gathers information from routine care on how localized rectal cancer is treated across Austrian hospitals. It aims to document the variety of treatment approaches, including total neoadjuvant therapy and immunotherapy, and their outcomes. By analyzing thi…
Sponsor: Austrian Breast & Colorectal Cancer Study Group • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Mapping how thyroid tumors spread and what surgery leaves behind
Knowledge-focused Not yet recruitingResearchers at Sohag University Hospitals are reviewing the medical records of 30 people treated for papillary thyroid cancer, the most common type of thyroid cancer. The study examines how far tumors extended beyond the thyroid gland and which complications appeared soon after s…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Hidden bacteria in prostate tumors may shape how the immune system fights cancer
Knowledge-focused Not yet recruitingResearchers at Anhui Medical University are studying bacteria found inside prostate tumors and how they relate to the immune system. The study uses leftover tissue samples and archived slides from about 100 men with prostate cancer or benign prostate disease. Scientists will sequ…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Prostate tumors hide a Nerve-Fueled neighborhood, and scientists are mapping it
Knowledge-focused Not yet recruitingResearchers at Anhui Medical University are studying how prostate cancer invades nerves, a feature linked to aggressive tumors and recurrence after surgery. They plan to collect tissue and clinical data from about 120 prostate cancer patients and compare nerve-invaded areas, ordi…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can Re-Assessing bile duct cancer treatment open the door to surgery?
Knowledge-focused Not yet recruitingResearchers at Karolinska University Hospital are following 900 people diagnosed with intrahepatic or perihilar cholangiocarcinoma, two types of bile duct cancer. The study tracks how tumors respond to treatment, how patients feel and function, and changes in biomarkers over time…
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can brain imaging unlock the secrets of opioid addiction?
Knowledge-focused Not yet recruitingResearchers at Yale University are using PET brain scans with a radioactive tracer called [11C]OMAR to measure CB1 receptor levels in people with opioid use disorder who are stabilized on buprenorphine, compared to healthy controls. The study aims to see if CB1 receptor availabil…
Phase 1 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Thyroid surgery under the microscope: what 3,000 real operations reveal
Knowledge-focused Not yet recruitingResearchers at a Moscow medical center are studying the quality and outcomes of thyroid surgery using real-world clinical data. The study follows patients who had thyroid operations for benign or malignant disease, tracking complications, cancer results, and long-term outcomes. B…
Sponsor: Pirogov Russian National Research Medical University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?
Knowledge-focused Not yet recruitingThis observational study tests whether artificial intelligence can predict how well pancreatic cancer responds to chemotherapy and how the disease may progress. Researchers will analyze data from 700 patients, including endoscopic ultrasound images, CT/MRI scans, lab results, and…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Doctors watch and learn: new study tracks endoscopy for pancreatic disease diagnosis
Knowledge-focused Not yet recruitingThis study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can frailty predict recovery after gastric cancer surgery?
Knowledge-focused Not yet recruitingThis study follows 328 adults aged 60 and older who are having surgery for gastric cancer. Researchers will measure frailty, nutrition, and muscle mass before surgery, then track complications, delirium, and recovery afterward. The goal is to see whether these factors, along with…
Sponsor: Kocaeli City Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Mapping Real-World care for stomach cancer in greece
Knowledge-focused Not yet recruitingThis observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can a single surgery technique improve life after stomach cancer in two countries?
Knowledge-focused Not yet recruitingThis study looks back at medical records from high-volume hospitals in Russia and China to compare how patients with stomach cancer or cancer at the junction of the stomach and esophagus fare after a specific surgery called proximal gastrectomy with double-tract reconstruction. R…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Personalized liver cancer treatment: a quest for predictive biomarkers
Knowledge-focused Not yet recruitingThis observational study follows 400 people with intermediate to advanced or unresectable hepatocellular carcinoma (the most common type of liver cancer) who are receiving systemic therapies such as atezolizumab plus bevacizumab or nivolumab plus ipilimumab, sometimes combined wi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may spot hidden stomach cancer recurrence risk
Knowledge-focused Not yet recruitingThis study enrolls adults with stomach or gastroesophageal junction cancer who had a strong response to chemotherapy before surgery, with no or very little cancer left in the removed tissue. Researchers will use a personalized blood test that tracks tumor DNA to see if it can ide…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can we decode pancreatic cancer's resistance to chemotherapy?
Knowledge-focused Not yet recruitingThis study enrolls 150 adults with suspected or confirmed pancreatic cancer who are scheduled for chemotherapy. Researchers will collect tumor samples via endoscopic ultrasound before and during treatment to analyze gene activity. They aim to understand how the cancer changes acr…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a new model forecast liver cancer in hepatitis b?
Knowledge-focused Not yet recruitingThis study aims to build and test a model that predicts the risk of developing liver cancer (hepatocellular carcinoma) in people with hepatitis B-related liver fibrosis or cirrhosis. Researchers will analyze data from 2000 patients, including their medical history, blood sugar ma…
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
New short camera could slash waiting lists for bowel cancer checks
Knowledge-focused Not yet recruitingThis study tests a new short camera called a rectoscope to check the lower bowel after rectal tumour removal. The goal is to see if it can be used in the clinic with a simple enema instead of strong bowel prep, making follow-up checks faster and reducing waiting lists. Thirty pat…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
A phone call could unlock early cancer detection for High-Risk groups
Knowledge-focused Not yet recruitingThis study tests a remote education program to help people at higher risk for pancreatic cancer learn about genetic testing and a blood test that screens for multiple cancers. The program targets Black, Latino/a, and Medicaid-enrolled individuals in Massachusetts who may have had…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can a pill rewrite the genetic story of resistant kidney cancer?
Knowledge-focused Not yet recruitingThis pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can pancreatic Cancer's inflammatory footprint be stopped?
Knowledge-focused Not yet recruitingThis observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Could a simple scan and blood test outsmart liver cancer?
Knowledge-focused Not yet recruitingThis study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …
Sponsor: D'Or Institute for Research and Education • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Blood and gut clues may flag pancreatic cancer risk early
Knowledge-focused Not yet recruitingThis observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Which rectal cancer surgery preserves quality of life better? a study investigates
Knowledge-focused Not yet recruitingThis study looks at people who had surgery for advanced lower rectal cancer, comparing two procedures: one that removes the rectum and anus (requiring a permanent stoma) and one that removes the rectum but keeps the anus (with a reconnection). The goal is to see which approach le…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may decide who needs surgery for rectal cancer
Knowledge-focused Not yet recruitingThis phase 2 trial tests whether a highly sensitive blood test (ctDNA) can help manage treatment for 200 people with early-stage rectal cancer. After standard chemotherapy and radiation, some patients will have their treatment guided by the blood test results instead of immediate…
Phase 2 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New blood test may spot hidden pancreatic cancer earlier after surgery
Knowledge-focused Not yet recruitingThis study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Ancient wisdom meets modern oncology: can TCM body types forecast treatment side effects?
Knowledge-focused Not yet recruitingThis study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…
Sponsor: Affiliated Hospital of Chengde Medical University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Artificial intelligence may predict ovarian cancer recurrence — a large study puts it to the test
Knowledge-focused Not yet recruitingThis study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that for…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Exercise after breast cancer: which workout best boosts healing muscle signals?
Knowledge-focused Not yet recruitingThis pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Scientists probe tumor environment to predict drug resistance in stomach cancer
Knowledge-focused Not yet recruitingThis study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Blood test and AI team up to outsmart colon cancer recurrence
Knowledge-focused Not yet recruitingThis study explores whether combining artificial intelligence analysis of tumor tissue with special blood tests (liquid biopsy) can more accurately predict if colon cancer will return after surgery. Researchers will follow 400 adults with stage II or III colon cancer for up to fi…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists launch study to decode why diabetes affects people differently
Knowledge-focused Not yet recruitingThe EXPAND study is a research project that will enroll 440 adults with and without pancreatic conditions to understand why type 2 diabetes varies so much from person to person. Researchers will collect data on metabolism, genetics, and pancreas health to identify distinct diabet…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New blood test may predict infection risk after liver transplant
Knowledge-focused Not yet recruitingThis study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Prostate cancer imaging gets a direct hit: artery injection may sharpen scans
Knowledge-focused Not yet recruitingThis study tests whether injecting a radioactive tracer directly into the prostate artery improves imaging compared to standard arm injection in 10 men with high-risk prostate cancer. The goal is to see if this method gives clearer pictures and helps predict the right radiation d…
Sponsor: Lithuanian University of Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI reads CT scans to predict which lung nodules turn cancerous
Knowledge-focused Not yet recruitingThis study will develop an artificial intelligence model that uses a patient's series of CT scans over time to predict whether a lung nodule will grow or become cancerous. Researchers will analyze scans from nearly 5,000 people to train the AI to recognize different growth patter…
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
Knowledge-focused Not yet recruitingThis study is testing whether a green dye called indocyanine green (ICG) can help surgeons see and remove lymph nodes that contain cancer during laparoscopic colon cancer surgery. About 25 adults with colon cancer will receive the dye injected around the tumor and into a vein. Th…
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study aims to spot hidden cancer spread in lobular breast cancer
Knowledge-focused Not yet recruitingThis study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months…
Sponsor: KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Scientists map hidden paths of colorectal cancer spread
Knowledge-focused Not yet recruitingThis study looks at where cancer spreads to lymph nodes in people with colon or rectal cancer. Researchers will examine tissue from 1200 patients who had surgery to remove their cancer. The goal is to find patterns that could help doctors better plan treatment in the future.
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks polyp return rates to improve Follow-Up care
Knowledge-focused Not yet recruitingThis study looks at how often polyps in the stomach or colon grow back after being removed during a scope procedure. Researchers will follow about 2,000 adults for up to three years to track recurrence and identify risk factors like polyp size, lifestyle, and health history. The …
Sponsor: LanZhou University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to unlock genetic secrets of lung cancer spread
Knowledge-focused Not yet recruitingThis study looks at a specific type of lung cancer called lung adenocarcinoma and how it can spread through tiny air spaces in the lungs. Researchers will collect tumor and healthy tissue samples from 140 patients to find genetic markers that might predict this spread. The goal i…
Sponsor: Universidade Nova de Lisboa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to refine who gets a liver transplant for cancer
Knowledge-focused Not yet recruitingThis study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Blood test may spare thousands from unnecessary colon surgery
Knowledge-focused Not yet recruitingThis study will collect blood samples from 1,000 people with small colon growths to see if a liquid biopsy can accurately tell benign from malignant lesions and predict cancer spread to lymph nodes. Current methods often lead to unnecessary surgery. The goal is to create a bioban…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
No-Scar surgery for endometrial cancer? new study tests vNOTES against standard laparoscopy
Knowledge-focused Not yet recruitingThis study compares two minimally invasive surgical methods for early-stage endometrial cancer: standard laparoscopy (small abdominal cuts) and vNOTES (surgery through the vagina with no visible scars). Researchers will enroll 160 women to see how well each method finds sentinel …
Sponsor: Cukurova University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Gene test could tailor chemo for tough pancreatic cancers
Knowledge-focused Not yet recruitingThis study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Lifestyle tweaks may cut liver cancer risk, new study hints
Knowledge-focused Not yet recruitingThis study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Massive french study to reveal best way to harvest donor livers
Knowledge-focused Not yet recruitingThis large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the be…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
AI could help pick surgery or ablation for liver cancer patients
Knowledge-focused Not yet recruitingThis study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Tumor DNA in fluids may predict peritoneal metastasis risk
Knowledge-focused Not yet recruitingThis study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Blood test may let some stomach cancer patients skip harsh chemo
Knowledge-focused Not yet recruitingThis study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa g…
Sponsor: Natera, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
300 rectal cancer Patients' tissues analyzed to unlock secrets of treatment response
Knowledge-focused Not yet recruitingThis study will look at tumor samples and health records from 300 people who had surgery for rectal cancer. The goal is to find patterns in the tumor's immune environment that can predict which patients will respond well to chemotherapy or immunotherapy. This could help doctors i…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Major trial asks: is radiation necessary for Low-Risk breast lesions?
Knowledge-focused Not yet recruitingThis study looks at women with a very early form of breast cancer called DCIS. It uses a special test to find those at low risk of the cancer coming back. The goal is to see if these low-risk women can skip radiation therapy after their lump-removal surgery without a meaningful i…
Phase 3 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
1,000 patients to help unlock secrets of liver surgery recovery
Knowledge-focused Not yet recruitingThis study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…
Sponsor: Azienda USL Toscana Centro • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Genetic score may spot pancreatic cancer risk early
Knowledge-focused Not yet recruitingThis study looks at whether a polygenic risk score—a measure based on many small genetic variations—can help predict who might develop pancreatic ductal adenocarcinoma (PDAC). Researchers will compare the genetic profiles of about 1,140 people with and without the disease. The go…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Old tumor samples may hold key to future biliary cancer treatments
Knowledge-focused Not yet recruitingThis study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The …
Sponsor: MedSIR • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Can a bioreactor predict ovarian cancer chemo success?
Knowledge-focused Not yet recruitingThis study aims to see if a special device called a U-Cup bioreactor can predict how well standard chemotherapy will work in women with high-grade ovarian cancer. Researchers will take tumor samples from 120 patients before treatment and test them in the lab. The goal is to find …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Blood tests and patient surveys could improve bile duct cancer monitoring
Knowledge-focused Not yet recruitingThis study aims to learn if blood tests for cancer DNA (ctDNA) and patient-reported quality of life can help doctors predict how bile duct cancer will progress and whether treatments are working. Researchers will collect blood samples and surveys from 300 patients with curable or…
Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Genetic risk profiles could change how we monitor Barrett's esophagus
Knowledge-focused Not yet recruitingThis study looks at whether sharing genetic risk information with Barrett's esophagus patients can improve their quality of life and reduce cancer worry. Researchers will collect tissue samples and use genetic analysis to create risk profiles. Half of the 266 participants will le…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Bile drain before pancreatic surgery: help or hindrance?
Knowledge-focused Not yet recruitingThis study looks at whether draining a blocked bile duct before surgery for pancreatic cancer changes the tumor's behavior or patient survival. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. They will compare those who …
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Virtual twins could unlock secrets of fatty liver and heart risk
Knowledge-focused Not yet recruitingThis study aims to create detailed computer models, or 'virtual twins,' of people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). By analyzing data from over 7,700 adults, researchers hope to better understand how the disease progresses and predict who migh…
Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Breast reconstruction study tests expanders beyond approved use
Knowledge-focused Not yet recruitingThis study will compare two different tissue expanders used in breast reconstruction after mastectomy in 80 women. Some participants will also receive radiation therapy, which is not typically recommended with these devices. Researchers will evaluate aesthetic outcomes, patient s…
Sponsor: Medical University Innsbruck • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Can early gene testing unlock better cancer treatments?
Knowledge-focused Not yet recruitingThis study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Will a prepackaged diet make colonoscopy prep easier?
Knowledge-focused Not yet recruitingThis study tests whether a prepackaged low-residue diet (Colobox) helps clean the colon better than just following oral and written instructions before a colonoscopy. Around 230 adults will be randomly assigned to one of two diet plans for 24 hours before the procedure. The goal …
Sponsor: Clinique Paris-Bercy • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Blood test may replace scans for liver cancer treatment monitoring
Knowledge-focused Not yet recruitingThis study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…
Sponsor: University of Belgrade • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
AI and 3D imaging aim to revolutionize bile duct surgery
Knowledge-focused Not yet recruitingThis study aims to create a 3D model of the bile ducts using MRI and CT scans, along with an AI tool to help doctors guide a camera during a procedure called ERCP. The goal is to improve safety and accuracy. The study will use existing medical images from 100 adult patients who h…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Study aims to find best surgery to preserve fertility in cervical cancer patients
Knowledge-focused Not yet recruitingThis study reviews past research and hospital data to compare three types of fertility-sparing surgeries for cervical adenocarcinoma: conization, simple trachelectomy, and radical trachelectomy. The goal is to see which offers the best balance between controlling cancer and allow…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Protein clue may predict ovarian cancer outcomes
Knowledge-focused Not yet recruitingThis study looks at a protein called DHODH in tissue from 72 women with a type of ovarian cancer. Researchers want to see if the amount of this protein can help predict how well chemotherapy works and how long patients live. The goal is to better understand the disease, not to te…
Sponsor: Heba Ahmed Mohamed • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
New study tests if removing rectal tumors through the anus reduces pain and wound issues
Knowledge-focused Not yet recruitingThis study looks at two ways to remove rectal cancer tumors. The newer method removes the tumor through the anus, avoiding extra cuts in the belly. The goal is to see if this leads to fewer wound problems and less pain after surgery. The study will review records from 190 adult p…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
French study to track endoscopic surgery for early esophageal cancer in 750 patients
Knowledge-focused Not yet recruitingThis study will follow 750 adults in France who undergo endoscopic submucosal dissection (ESD) for early esophageal cancer or precancerous Barrett's esophagus. Researchers will track how well the procedure removes the cancer, how often it comes back, and whether additional treatm…
Sponsor: Société Française d'Endoscopie Digestive • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Are doctors missing hidden cancer clues? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether doctors are properly reporting small cancer spots called tumor deposits in people with rectal cancer. These spots can show if the cancer is more aggressive and might need extra treatment like chemo or radiation. Researchers will compare reports from be…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Could a COVID shot boost cancer treatment? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Protein fingerprint may forecast liver cancer 15 years early
Knowledge-focused Not yet recruitingThis study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Rare gene defect may fuel liver cancer in otherwise healthy livers
Knowledge-focused Not yet recruitingThis study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study tracks immune therapy results in advanced liver cancer
Knowledge-focused Not yet recruitingThis study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-w…
Sponsor: Ahmed Karam Helmy • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can a 30-minute bike ride help fight liver cancer? scientists investigate.
Knowledge-focused Not yet recruitingThis study will look at how a single 30-minute bike ride changes levels of certain liver proteins (FGF21 and follistatin) in 12 people with liver cancer. Researchers want to understand how exercise affects the body in these patients, which could lead to better exercise recommenda…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Gene variants may raise lung cancer risk in Never-Smokers
Knowledge-focused Not yet recruitingThis study will analyze genetic data from 100,000 people to see if variations in aldehyde-metabolizing genes (ADH1B and ALDH family) are linked to lung cancer risk, especially in people who have never smoked. The goal is to understand how these genes might influence the developme…
Sponsor: Kaohsiung Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New study aims to predict bleeding and clotting risks in cancer patients
Knowledge-focused Not yet recruitingThis observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test after surgery could spot hidden cancer cells
Knowledge-focused Not yet recruitingThis study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Could Omega-6 fats signal liver cancer risk?
Knowledge-focused Not yet recruitingThis observational study will measure Omega-6 fatty acid levels in the blood of 100 adults — half with liver cancer and half without — to see if there is a connection. No drugs or treatments are given. The goal is to understand if these fats are linked to the presence or severity…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Gut bacteria may hold key to better nutrition for cancer patients
Knowledge-focused Not yet recruitingThis study looks at how the bacteria in the gut and mouth relate to nutrition in 150 adults with digestive cancer starting chemotherapy. Researchers will collect stool and saliva samples, along with questionnaires and tests, before and after the first chemo cycle. The goal is to …
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Blood particle test may predict liver failure and cancer risk
Knowledge-focused Not yet recruitingThis study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC